Five Prime Therapeutics Stock Analysis (NASDAQ:FPRX)

Add to My Stocks
$35.98 $1.09 (3.12%) FPRX stock closing price Mar 24, 2017 (Closing)
Watch Robo Advisor Video of FPRX Stock Analysis
Five Prime Therapeutics
Updated on : Mar 24, 2017
previous close
FPRX 36 (0%)
S&P 500 2344 (0%)
Closing Price On: Mar 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-323.2%
Sector Average:
-6.4%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Cash Flow
Operating cash flow:
-$14.9M
Net Income:
-$20.1M
PROS      CONS
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
FPRX PS :
32.2
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-15.8%
Free Cash Flow Margin:
-190.8%
Double Tap To Exit Full Screen
0:00
/

Five Prime Therapeutics Analysis Video

123 5 2

View Five Prime Therapeutics stock analysis video. This is our FPRX analyst opinion covering the buy and sell arguments for FPRX stock.

Five Prime Therapeutics Inc Stock Rating (2.2/5)

Our Five Prime Therapeutics stock opinion is based on fundamentals of the company. This Five Prime Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy FPRX stock?

Should you sell FPRX stock?

  • Five Prime Therapeutics registered a negative operating margin of -323.2% (average) over the Trailing Twelve Months (TTM).
  • Over the last 12 months, Five Prime Therapeutics had an average Net loss of -214.1%.
  • PE ratio is meaningless for FPRX stock as the company has losses.
  • The company is trading at a price to sales multiple of 32.2, which is higher in comparison to the Medical-Biomed-Genetics industry average of 4.7, making FPRX stock expensive.
  • A negative ROE of -15.8% indicates that the company is not able to generate profits with the money shareholders have invested.
  • Five Prime Therapeutics has a negative FCF (Free Cash Flow) margin of -190.8%.

Comments on this video and Five Prime Therapeutics stock